Physicians from NYU Langone Health and its Perlmutter Cancer Center successfully treated their first patient in an NIH/NCI- sponsored clinical trial using CivaSheet® ,to improve lung cancer patients’ outcomes.
Kasada, an online traffic integrity solution that accurately detects and defends against bot attacks announced revenue growth of more than 100%.
The "Pharmaceutical Glass Packaging Market - Growth, Trends, and Forecasts (2020-2025)" report has been added to ResearchAndMarkets.com's offering.
The U.S. dollar fell on Tuesday despite rising worries about a second wave of COVID-19 infections, as investors sat on the sidelines ahead of next week's U.S. election. Monday saw the steepest stock market sell-off in a month and a bond rally, but foreign exchange market activity has remained relatively muted, with price moves on Tuesday limited.
Real Brands Inc. Thom Kidrin has been named CEO of Real Brands Inc. following its merger with Canadian American Standard Hemp Inc., where he was CEO. Real Brands Inc. With the merger, Real Brands’ primary business is hemp CBD oil/isolate extraction, wholesaling of CBD oils and isolate, and production and sales of hemp-derived CBD consumer brands. * Brings together proprietary hemp-derived CBD extraction, wholesale CBD oils/isolates, CBD product formulations and consumer brands into public entity * Real Brands appoints Thom Kidrin as CEONorth Providence, RI and Weston, FL, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Real Brands Inc. (OTCPK: RLBD) has completed a reverse merger to acquire Canadian American Standard Hemp Inc., (CASH) effective immediately. Real Brands’ name and trading symbol will be maintained, with CASH shareholders acquiring majority control of Real Brands. CASH will continue to operate as a wholly-owned subsidiary of Real Brands. Thomas Kidrin, CEO of CASH, has been named Chief Executive Officer (CEO) of Real Brands, replacing former Real Brands CEO Jerry Pearring.Real Brands’ new headquarters will be the newly renovated/constructed CASH headquarters and hemp processing facility at 12 Humbert St., in North Providence, RI.“This strategic merger with Real Brands is designed to drive increased shareholder value and provide the public with an opportunity to participate in the growing global hemp-derived CBD market,” stated Thom Kidrin, new CEO of Real Brands. “With access to the capital markets now, we anticipate it will be easier and faster to fund our next phases of expected growth.”CASH is an early entrant in the hemp-derived CBD market, specializing in hemp CBD oil/isolate extraction, wholesaling of CBD oils and isolate, and production and sales of hemp-derived CBD consumer brands. Its Halo 5 is a proprietary chromatography extraction technology utilizing a Simulated Moving Bed (SMB) engineered process for chromatographic separation. The SMB process is advantageous inasmuch as it provides large quantities of highly purified material and precise pharmaceutical grade molecular separation at dramatically reduced costs.All of CASH’s hemp processing capabilities and brands, including American Standard Hemp® (A.S.H. ®), WA® and Zen Pets Treats™, and proprietary product formulations created by world renowned chemist Dr. Adel Rammal, PhD. will be retained following the merger. Dr. Rammal previously served as CASH’s Chief Scientific Officer and will be staying on at Real Brands in that capacity. Following the merger, CASH will continue to own and operate its web sites: www.cashinc.com; wabrands.com; ZenPetsTreats.com and americanstandardhemp.com.Real Brands’ multiple existing CBD brands including CBD Pharmacy®, Omega Hemp®, and Humboldt® were not included in the merger and will be owned by a separate entity.The acquisition of CASH brings with it CASH’s affiliation with Turning Point Brands, Inc. (NYSE: TPB), a strategic equity shareholder and investor in CASH, as well as a customer for bulk CBD oils and isolates used in Turning Point products. Turning Point has more than 250,000 points of distribution with leading brands such as Zig-Zag®, Stoker’s®, and Beech Nut®.“Our strategic relationship with TPB is invaluable, as they offer unique expertise and experience in brand launch and marketing, in addition to being a valued major customer,” noted Kidrin.“We are pleased to complete this transaction with CASH and believe the combined companies will provide increased value to our current shareholders that far exceeds the value of the two entities separately,” said, Jerry Pearring, former CEO of Real Brands “There are real synergies between the two companies and I am confident their strategic plans promise a bright future for the shareholders.”Peter N. Christos, a member of the Board of Directors for both Real Brands and CASH, assisted in facilitating the merger and stated, “Knowing both Thom Kidrin and Jerry Pearring for decades, and the many shared resources between the two companies, the idea of this merger was natural. Enabling CASH to become a publicly traded entity via this transaction should allow the organization to more quickly take advantage of its growing opportunities. I expect this merger will be advantageous to both companies’ respective shareholders.”Follow us on social media: https://www.facebook.com/RealBrandsUSA/ Contacts: Media Relations: Accentuate PR, Julie Shepherd 847 275 3643, firstname.lastname@example.org Sales/Investors: 617-725-8900, email@example.comAbout Real Brands Inc.Real Brands is the result of a 2020 merger with Canadian American Standard Hemp Inc. (CASH) that brought together industrial scale hemp CBD oil/isolate extraction and processing, wholesaling of CBD oils and isolate, and production and sales of numerous hemp-derived CBD consumer brands of smokable, edible and topical products. Its Halo 5 is a proprietary chromatography extraction technology utilizing a Simulated Moving Bed (SMB) that provides the advantage of producing large quantities of highly purified material and precise pharmaceutical grade molecular separation at dramatically reduced costs. Visit www.realbrandsusa.com. Consumer product lines are available on www.wabrands.com, and www.americanstandardhemp.com.Forward-Looking StatementsThis release contains certain forward-looking statements and information relating to Real Brands, Inc. that are based on the beliefs of Real Brands' management, as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events including estimates and projections about its business based on certain assumptions of its management, including those described in this Release. These statements are not guarantees of future performance and involve risk and uncertainties that are difficult to predict. Additional risk factors are included in the Company’s public filings with the OTC. Should one or more of these underlying assumptions prove incorrect, actual results may vary materially from those described herein as “hoped,” “anticipated,” “believed,” “confident,” “estimated,” “should,” “preparing,” “expected” or words of a similar nature. The Company does not intend to update these forward-looking statements. The content of any websites referenced herein are not incorporated into this release.Attachments * Real Brands Inc. * Real Brands Inc.
Calyxt, Inc. (NASDAQ: CLXT), a plant-based technology company, will host a Virtual Analyst Day on Tuesday, November 17, 2020 at 4:00 p.m. Eastern time.
GOLETA, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Resonant Inc. (NASDAQ: RESN), a leader in transforming the way radio frequency, or RF, front-ends are being designed and delivered for mobile handsets and wireless devices, will release financial results for the third quarter ended September 30, 2020 after market close on Tuesday, November 10, 2020. Management will host a conference call on Tuesday, November 10, 2020, at 1:30 p.m. Pacific standard time (4:30 p.m. Eastern standard time) to discuss Resonant’s third quarter 2020 financial results. The call will conclude with Q&A from participants. To participate, please use the following information:Q3 2020 Conference Call and Webcast Date: Tuesday, November 10, 2020 Time: 1:30 p.m. Pacific standard time (4:30 p.m. Eastern standard time) U.S. Dial-In: 1-877-423-9813 International Dial-In: 1-201-689-8573 Conference ID: 13711933 Webcast: http://public.viavid.com/index.php?id=141977Please dial in at least 10 minutes before the start of the call to ensure timely participation.A playback of the call will be available through December 10, 2020. To listen, call 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally and enter replay pin number 13711933. A webcast will also be available for 30 days on the IR section of the Resonant website or by clicking the webcast link above.About Resonant Inc.Resonant (NASDAQ: RESN) is transforming the market for RF front-ends (RFFE) by disrupting the RFFE supply chain through the delivery of solutions that leverage our Infinite Synthesized Network (ISN) software tools platform, capitalize on the breadth of our IP portfolio, and are delivered through our services offerings. In a market that is critically constrained by limited designers, tools and capacity, Resonant addresses these critical problems by providing customers with ever increasing design efficiency, reduced time to market and lower unit costs. Customers leverage Resonant’s disruptive capabilities to design cutting edge filters and modules, while capitalizing on the added stability of a diverse supply chain through Resonant’s fabless ecosystem-the first of its kind. Working with Resonant, customers enhance the connectivity of current mobile devices, while preparing for the demands of emerging 5G applications. To learn more about Resonant, view the series of videos published on its website that explain Resonant's technologies and market positioning: * Resonant Corporate Video * ISN and XBAR: Speeding the Transition to 5G * Infinite Synthesized Networks, ISN Explained * What is an RF Filter? * RF Filter Innovation * Transforming the Mobile Filter Supply ChainFor more information, please visit www.resonant.com. Resonant uses its website and LinkedIn page as channels of distribution of information about its products, its planned financial and other announcements, its attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and Resonant may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor the company’s website and its social media accounts in addition to following the company’s press releases, SEC filings, public conference calls, and webcasts.About Resonant’s ISN® TechnologyResonant can create designs for difficult bands, modules and other complex RF Front End requirements that we believe have the potential to be manufactured for less cost and less time than traditional approaches. ISN is a suite of proprietary mathematical methods, software design tools and network synthesis techniques that enable us to explore a much larger set of possible design solutions that regularly incorporate our proprietary technology. We then quickly deliver design simulations to our customers, which they manufacture or have manufactured by one of our foundry partners. These improved solutions still use Surface Acoustic Wave (SAW) or Temperature Compensated Surface Acoustic Wave (TC-SAW) manufacturing methods and perform as well as those using higher cost manufacturing methods such as Bulk Acoustic Wave (BAW). Resonant's method delivers excellent predictability, enabling achievement of the desired product performance in roughly half as many turns through the fab. In addition, because Resonant's models are fundamental, integration with its foundry and fab customers is seamless because its models speak the "fab language" of basic material properties and dimensions.Investor Relations Contact: Greg Falesnik or Luke Zimmerman MZ Group - MZ North America (949) 259-4987 RESN@mzgroup.us www.mzgroup.us
The "United States Vertical Farming Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.
Satisfaction with restaurants was heading in the wrong direction well before the pandemic upended the industry.
Image source: The Motley Fool. Shinhan Financial Group Co, Ltd. (NYSE: SHG)Q3 2020 Earnings CallOct 27, 2020, 3:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Cheol-Woo Park -- Head of Investor RelationsGreetings.
SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (NASDAQ: GHSI) is providing the following answers to frequently asked questions to its stockholders with regard to Proposal 4, which is being considered at the Company’s Annual Stockholders’ Meeting (the “Annual Meeting”) on October 29, 2020. Only stockholders of record on September 1, 2020, or the record date, are eligible to attend and vote on proposals presented at the Annual Meeting. The Board recommends a vote “FOR” Proposal 4. IMPORTANT REMINDER FOR GUARDION HEALTH SCIENCES, INC. STOCKHOLDERSTime is short – please vote your shares for the Annual Meeting of Stockholders on October 29, 2020Your vote may impact the value of your investment and the future of Guardion Health Sciences, Inc.KEY QUESTIONS OUR STOCKHOLDERS ARE ASKING REGARDING PROPOSAL 4: EXTENSION OF PREVIOUSLY AUTHORIZED REVERSE STOCK SPLITQuestionAnswer What will happen to Guardion Health Sciences, Inc. if Proposal 4 (Extension of Previously Authorized Reverse Stock Split) does not pass? Your vote “FOR” Proposal 4 at the Annual Meeting of Stockholders on October 29, 2020 is critically important. Guardion Health Sciences, Inc. is at risk of being delisted from the Nasdaq Capital Market after November 30, 2020. Such delisting would adversely impact the liquidity of the Company’s common stock. Nasdaq requires that a Company maintain a minimum bid price of $1.00 per share. The Company is requesting from its stockholders an extension of its current authorization to effectuate a reverse stock split (which expires December 5, 2020) to increase the per share price and bid price of the Company’s common stock in order to regain compliance with the $1.00 minimum bid price requirement of Nasdaq. Additionally, a reverse stock split would potentially make the Company’s common stock more attractive to certain institutional investors, which would provide for a stronger investor base. If Proposal 4 is not approved, the Board of Directors will initiate the previously authorized reverse stock split in November 2020 in order to comply with Nasdaq’s continued listing requirements. If Proposal 4 is approved, we intend to appeal any delisting order that Nasdaq issues after November 30, 2020, as we believe that having the continuing discretionary authority to implement a reverse stock split will increase the Company’s chances of receiving temporary relief (not to exceed 180 days from November 30, 2020) from Nasdaq. Such temporary relief will allow the Company additional time to execute on its business initiatives to generate greater stockholder value and hopefully increase the Company’s common share price. The board of directors believes it is in your best interest to vote “FOR” Proposal 4 today. Didn’t Stockholders authorize a Reverse Stock Split at last year’s annual meeting? Why is my vote so important? Yes, our stockholders authorized a reverse stock split at last year’s annual meeting of stockholders to be effectuated up until December 5, 2020. To date, the Board of Directors has not implemented the reverse stock split. We are requesting an extension of that previous authorization from our stockholders so that our Board of Directors retains the flexibility necessary should a reverse stock split become necessary. Approval of Proposal 4 requires support by at least a majority of the outstanding shares of common stock. So, while many Guardion Health Sciences, Inc. stockholders have been highly supportive of Proposal 4 to date, we have not yet received enough votes to meet that high standard. That is why your vote matters, no matter how many or how few common shares you own. What happens if I don’t vote?If you don’t vote or you abstain, it may count the same as a vote AGAINST Proposal 4. Who can help me vote?Our proxy solicitor, Kingsdale Advisors, can assist you with voting your shares and any questions you may have – please see below for their contact information. If I’ve already voted, can I change my vote?Yes. You may revoke your previously submitted proxy and reclaim your right to vote at any time before your proxy is voted at the Annual Meeting by submitting a later-dated proxy card or vote instruction form or by voting in person at the Annual Meeting. Your most current proxy card or Internet proxy is the one that will be counted. Your vote is important, so please act today! Our proxy solicitor, Kingsdale Advisors, can assist in this process as well – please see below for their contact information. OUR PROXY SOLICITOR (KINGSDALE ADVISORS) STANDS READY TO ASSIST YOU WITH THIS IMPORTANT VOTE If you have questions about how to vote your shares, please contact our proxy solicitor, Kingsdale Advisors Strategic Stockholder Advisor and Proxy Solicitation Agent 745 Fifth Avenue, 5th Floor, New York, NY 10151 North American Toll Free Phone: 1-866-229-8874 Email: firstname.lastname@example.org Call Collect Outside North America: +1 (416) 867-2272 * * *This communication may be deemed to be solicitation material in respect of Proposal 4. On September 8, 2020, Guardion Health Sciences, Inc. filed a definitive proxy statement with the Securities and Exchange Commission (“Commission”) in connection with the 2020 Annual Stockholders’ Meeting. STOCKHOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE PROXY STATEMENT AND ANY OTHER SOLICITING MATERIALS THAT ARE FILED WITH THE COMMISSION WHEN THEY BECOME AVAILABLE BECAUSE THESE DOCUMENTS CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY AND THE PROPOSALS TO BE VOTED UPON. The Company’s proxy statement and any other solicitation materials filed by the Company with the Commission can be obtained free of charge at the Commission’s website at www.sec.gov and at the investor relations section of the Company’s website at https://guardionhealth.com/sec-filings/. Stockholders may also write to the Company at the following address to request copies of these materials: Guardion Health Sciences, Inc., 15150 Avenue of Science, Suite 200, San Diego, California 92128. The Company, its directors and certain of its officers will be participants in the solicitation of proxies from stockholders in respect of the Annual Meeting. The Company has also engaged Kingsdale Advisors to aid in the solicitation of proxies. Detailed information regarding the identity of participants, and their respective interests in the Company by security holdings or otherwise, are set forth in the definitive proxy statement for the Annual Meeting. The contents of the websites referenced above are not deemed to be incorporated by reference into the proxy statement. Forward-Looking Statement DisclaimerWith the exception of the historical information contained in this press release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward- looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company’s ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic on the Company’s business, operations and the economy in general, and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Investor Relations Contact:CORE IR Scott Arnold 516-222-2560 email@example.com
VANCOUVER, British Columbia, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Cornish Metals Inc. (TSX-V: CUSN) (“Cornish Metals” or the “Company”) is pleased to announce the appointment of John McGloin to the Board of Directors (the “Board’) as a non-executive Director. Mr. McGloin is based in the UK and currently serves as a non-executive Director of Perseus Mining Limited, and Amphi Capital Ltd., a non-executive independent Director of Caledonia Mining Plc., and the non-executive Chairman of Oriole Resources Plc., and is the former Chairman and Chief Executive of Amara Mining.Mr. McGloin is a geologist and graduate of Camborne School of Mines and worked for many years in Africa within the mining industry before moving into consultancy. He joined Arbuthnot Banking Group following four years at Evolution Securities as their mining analyst. He is also the former Head of Mining at Collins Stewart.Richard Williams, CEO of Cornish Metals, stated, “We are very pleased that John has agreed to join our Board. He not only has an extensive background in mining but also is very familiar with our flagship South Crofty tin project. This will be extremely valuable as we advance not only the South Crofty tin project, but also additional mineral rights located in Cornwall, UK.”ABOUT CORNISH METALS Cornish Metals (formerly Strongbow Exploration Inc.) completed the acquisition of the South Crofty tin project plus additional mineral rights located in Cornwall, UK, in July 2016 (see the Company’s news release dated July 12, 2016). The additional mineral rights cover an area of approximately 15,000 hectares and are distributed throughout Cornwall. Some of these mineral rights cover old mines that were historically worked for copper, tin, zinc, and tungsten.The South Crofty project covers the former producing South Crofty tin mine located in Pool, Cornwall. South Crofty mine closed in 1998 following over 400 years of continuous production. Since acquiring the project in 2016, Cornish Metals has completed and published maiden NI 43-101 mineral resources for South Crofty using the vast archive of historical production data and more recent drilling completed between 2007 and 2013. In 2017, Cornish Metals completed a Preliminary Economic Assessment that demonstrated the economic viability of re-opening the mine. Additionally, Cornish Metals has undertaken extensive pilot-scale water treatment trials and successfully applied for and received the necessary environmental permits to abstract, treat and discharge mine water in order to dewater the mine. Planning permissions for the operation of the mine and re-development of the surface facilities have been secured and construction of the water treatment plant foundations commenced. The dewatering pumps, variable speed drives and new high-voltage power supply have been delivered to site.ON BEHALF OF THE BOARD “Richard D. Williams” Richard D. Williams, P.GeoNeither TSX Venture Exchange nor its Regulations Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Caution regarding forward looking statements Certain of the statements made and information contained in this press release may constitute forward-looking information and forward-looking statements (collectively, “forward-looking statements”) within the meaning of applicable securities laws. All statements, other than statements of historical fact, are forward-looking statements. The words “will”, “expect”, “plan,” “intend” and similar expressions identify forward-looking statements. In particular, this press release contains forward-looking statements including, without limitation, with respect to the Incentive Program. Forward-looking statements, while based on management’s best estimates and assumptions, are subject to risks and uncertainties that may cause actual results to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: risks related to receipt of regulatory approvals, risks related to general economic and market conditions; risks related to the availability of financing; the timing and content of upcoming work programs; actual results of proposed exploration activities; possible variations in Mineral Resources or grade; failure of plant, equipment or processes to operate as anticipated; accidents, labour disputes, title disputes, claims and limitations on insurance coverage and other risks of the mining industry; changes in national and local government regulation of mining operations, tax rules and regulations. Although Cornish Metals has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Cornish Metals undertakes no obligation or responsibility to update forward-looking statements, except as required by law. CONTACT: For additional information please contact: Irene Dorsman at (604) 210 8752 or by e-mail at firstname.lastname@example.org or Sherman Dahl of Pretium Communications at (250) 558 8340. Blytheweigh (Financial PR/IR-London) Tel: +44 207 138 3204 Tim Blythe: email@example.com
Latest DSD supplier performance data vendor from ReposiTrak shows clients reducing OOS by 55%.
Appili Announces Additional $6.3MM US Funding for its ATI-1701 Biodefense Program, working with Ology Bio on a vaccine candidate against tularemia
Brand Expanding Into Providence, San Francisco and San JoseLeague City, Texas, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Muscle Maker, Inc. (Nasdaq: GRIL) the parent company of Muscle Maker Grill, Healthy Joe’s & MMG Burger Bar, a fast-casual concept known for serving “healthier for you” meals, today announced that the company, along with one of its franchise partners have signed agreements to open three delivery only ghost kitchens throughout the U.S. The first delivery only ghost kitchen will be located in downtown Providence Rhode Island and will be operated by Muscle Maker, Inc. Providence is home to many well-known universities such as Brown, Johnson and Wales, Providence College and The Rhode Island School of Design. Located amongst these institutions is a thriving business culture with high delivery potential. Within a three mile radius there are over 230,000 employees and 28,000 students.The company’s non-traditional growth model will now stretch from coast-to-coast with the openings of two ghost kitchens in two major metropolitan cities. The first will be located in downtown San Francisco and the other in downtown San Jose. Both of these locations will be operated by a local franchisee who also owns and operates the Antioch, CA location.Michael Roper, CEO of Muscle Maker Grill, commented, “As stated in recent press announcements, the company is following its non-traditional growth plans, and now we’ve got a dedicated franchise partner opening their first two delivery only ghost kitchen locations on the West Coast. The ghost kitchen model makes sense for the brand given the high delivery demand due to Covid, low cost of entry and ability to expand rapidly.”About Muscle Maker GrillFounded in 1995 in Colonia, New Jersey, Muscle Maker Grill features high quality, great tasting food, freshly prepared with proprietary recipes. The menu, created with the guest’s health in mind, is lean and protein based. It features all-natural chicken, grass fed steak, lean turkey, whole wheat pasta, wraps, bowls and more. It also offers a wide selection of fruit smoothies in a variety of assorted flavors, protein shakes and supplements. For more information on Muscle Maker Grill, visit www.musclemakergrill.com.Forward-Looking StatementsThis press release may include “forward-looking statements” pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. To the extent that the information presented in this press release discusses financial projections, information, or expectations about our business plans, results of operations, products or markets, or otherwise makes statements about future events, such statements are forward-looking. Such forward-looking statements can be identified by the use of words such as “should”, “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Although we believe that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in documents that we file from time to time with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained, and Muscle Maker, Inc does not undertake any duty to update any forward-looking statements except as may be required by law.Contact: Muscle Maker Grill Marketing: firstname.lastname@example.orgInvestor Relations: IR@musclemakergrill.com
LAS VEGAS, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Full House Resorts (NASDAQ: FLL) announced that it will report its third quarter 2020 and year-to-date financial results on Thursday, November 5, 2020, followed by a conference call at 4:30 p.m. ET (1:30 p.m. PT). Investors can access the live audio webcast from the Company’s website at www.fullhouseresorts.com under the investor relations section. The conference call can also be accessed by dialing (877) 226-2890 or, for international callers, (303) 223-0118. A replay of the conference call will be available shortly after the conclusion of the call through November 19, 2020. To access the replay, please visit www.fullhouseresorts.com. Investors can also access the replay by dialing (844) 512-2921 or, for international callers, (412) 317-6671 and using the passcode 21971273.Forward-looking Statements This press release may contain statements by Full House Resorts, Inc. that are "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Additional information concerning potential factors that could affect our financial condition and results of operations is included in the reports we file with the SEC, including, but not limited to, our Form 10-K for the most recently ended fiscal year and our other periodic reports filed with the SEC. We are under no obligation to (and expressly disclaim any such obligation to) update or revise our forward-looking statements as a result of new information, future events or otherwise, except as otherwise required by law. Actual results may differ materially from those indicated in the forward-looking statements.About Full House Resorts, Inc. Full House Resorts owns, develops and operates gaming facilities throughout the country. The Company’s properties include Silver Slipper Casino and Hotel in Hancock County, Mississippi; Bronco Billy's Casino and Hotel in Cripple Creek, Colorado; Rising Star Casino Resort in Rising Sun, Indiana; and Stockman’s Casino in Fallon, Nevada. The Company also operates the Grand Lodge Casino at the Hyatt Regency Lake Tahoe Resort, Spa and Casino in Incline Village, Nevada under a lease agreement with the Hyatt organization. Further information about Full House Resorts can be viewed on its website at www.fullhouseresorts.com and on its Facebook page at www.facebook.com/FHResorts. CONTACT: Contact: Lewis Fanger, Chief Financial Officer Full House Resorts, Inc. (702) 221-7800 www.fullhouseresorts.com
The Engine, the venture firm spun out of MIT that invests in early-stage Tough Tech companies solving some of the world’s biggest problems, announced today it has raised $230M toward its Fund II, bringing total capital commitments across its two funds to $435M. Since the launch of its first fund in 2017, The Engine has collaborated with leading research institutions to more quickly move innovation out of labs and into the market. The Engine’s initial fund has backed 27 companies that harness breakthrough science and technology, often from top research institutions, to solve important, global challenges across climate change, human health, and advanced systems. The Tough Tech investment firm will begin making investments from its Fund II this fall.
IDC Government Insights announced today that applications are open for the fourth annual Smart Cities North America Awards (SCNAA).
City of Hope will combine its world-leading expertise with NexImmune technology to explore tumor escape mechanisms and to identify unique leukemia stem cell targets for next generation immunotherapeuticsGAITHERSBURG, Md., Oct. 27, 2020 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biotechnology company developing unique non-genetically-engineered T cell immunotherapies, announced today that it has signed a research initiative related to its AIM nanoparticle technology with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases. City of Hope is a participating clinical site in the ongoing Phase 1/2 study of NEXI-001. The cancer center will leverage both patient samples from the ongoing NexImmune Phase 1/2 clinical study of NEXI-001 in acute myeloid leukemia (AML) patients with relapsed disease after allogeneic stem cell transplantation and the center’s tumor repository bank of primary leukemia samples, one of the largest collections in the world, to drive the research.NEXI-001 is a cellular product candidate that contains populations of naturally occurring CD8+ T cells directed against multiple antigen targets for AML, and it is the first clinical product generated by the Company’s AIM nanoparticle technology.“NexImmune has developed a unique and versatile technology platform that lends itself very effectively to important areas of ongoing research in the field of AML,” said Guido Marcucci, M.D., Chair and Professor with City of Hope’s Department of Hematologic Malignancies Translational Science. “Our collective goal is to translate future research findings into new, more effective T cell immunotherapies to the benefit of these very difficult to treat patients.” A key objective of the research will focus on the identification of new antigen targets that are expressed on both leukemic blasts as well as leukemic stem cells, and those which represent survival proteins to both. Once identified, these antigen targets will be loaded on NexImmune AIM-nanoparticles to expand antigen-specific CD8+ T cells, and evaluated in pre-clinical models for anti-tumor potency, tumor-specific killing, and response durability.In addition, the research initiative will aim to further understand different mechanisms of tumor escape, such as tumor antigen and human leukocyte antigen (HLA) downregulation due to immune pressure.“Research between NexImmune and City of Hope will inform a scientific understanding of how the immune system can address certain tumor escape mechanisms to more effectively fight aggressive cancers like AML, and how this might be accomplished with NexImmune’s AIM technology and T cell products,” said Monzr Al Malki, M.D., Director of City of Hope’s Unrelated Donor BMT Program and Haploidentical Transplant Program and an Associate Clinical Professor with Department of Hematology and Hematopoietic Cell Transplantation. “Based on our current clinical experience with this technology, we’re excited to learn what more this research will tell us.”“City of Hope is a world-class clinical research institution that has built one of the largest banks of leukemia samples in the world,” said Han Myint, M.D., NexImmune Chief Medical Officer. “The depth of expertise that Drs. Marcucci, Al Malki and their team bring to this research initiative will help NexImmune continue to develop innovative products that can help patients with AML and other hard-to-treat cancers.”City of Hope is a leader in bone marrow transplantation. More than 16,000 stem cell and bone marrow transplants have been performed at City of Hope, and more than 700 are performed annually. City of Hope’s BMT program is the only one in the nation that has had one-year survival above the expected rate for 15 consecutive years, based on analysis by the Center for International Blood and Marrow Transplant Research.About NexImmune NexImmune is a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIM) technology. The AIM technology is designed to generate a targeted T cell-mediated immune response and is initially being developed as a cell therapy for the treatment of hematologic cancers. AIM nanoparticles (AIM-np) act as synthetic dendritic cells to deliver immune-specific signals to targeted T cells and can direct the activation or suppression of cell-mediated immunity. In cancer, AIM-expanded T cells have demonstrated best-in-class anti-tumor properties as characterized by in vitro analysis, including a unique combination of anti-tumor potency, antigen target-specific killing, and long-term T cell persistence. The modular design of the AIM platform enables rapid expansion across multiple therapeutic areas, with both cell therapy and injectable products.NexImmune’s two lead T cell therapy programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to >3 prior lines of therapy, respectively. The Company’s pipeline also has additional preclinical programs, including cell therapy and injectable product candidates, for the treatment of oncology, autoimmune disorders, and infectious diseases.For more information, visit www.neximmune.com.Media Contact: Mike Beyer Sam Brown Inc. Healthcare Communications 312-961-2502 email@example.comInvestor Contact: Chad Rubin Solebury Trout +1-646-378-2947 firstname.lastname@example.org
Ology Bioservices announced that the DOD has awarded the company with a contract to manufacture a novel live attenuated tularemia vaccine.